Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Simulect 20 mg powder and solvent for solution for injection or infusion Simulect 20 mg powder for solution for injection or infusion · Abschnitt 4.5 · PDF-Seite 5
In the original phase III studies during the first 3 months post-transplantation, 14% of patients in the
basiliximab group and 27% of patients in the placebo group had an acute rejection episode treated with
antibody therapy (OKT 3 or antithymocyte globulin/antilymphocyte globulin [ATG/ALG]), with no
increase in adverse events or infections in the basiliximab group as compared to placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): placebo (HOS-088378)
Version 2025-12-19T11:51:00Z · SHA-256 733fba3a740348b21107babe9d9387936dfd68357cde53822fb186eb4a9d7e0d · Passage 944dd2ff5cb6a830b9a351682081aaa20bd0abcdc7c9ef7c7642176f7d4be91a · Zeichen 1050–1441 im Abschnitt
Wechselwirkungen · Simulect
Simulect 20 mg powder and solvent for solution for injection or infusion Simulect 20 mg powder for solution for injection or infusion · Abschnitt 4.5 · PDF-Seite 5
Three clinical trials have investigated basiliximab use in combination with a triple therapy regimen
which included either azathioprine or mycophenolate mofetil. The total body clearance of basiliximab
was reduced by an average 22% when azathioprine was added to a regimen consisting of ciclosporin
for microemulsion and corticosteroids. The total body clearance of basiliximab was reduced by an
average 51% when mycophenolate mofetil was added to a regimen consisting of ciclosporin for
microemulsion and corticosteroids. The use of basiliximab in a triple therapy regimen including
azathioprine or mycophenolate mofetil did not increase adverse events or infections in the basiliximab
group as compared to placebo (see section 4.8).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-12-19T11:51:00Z · SHA-256 733fba3a740348b21107babe9d9387936dfd68357cde53822fb186eb4a9d7e0d · Passage d9ac0d08b763395ed52ccfd6a3db09312ae59258cd52ba42239ca8173921e687 · Zeichen 1443–2177 im Abschnitt
Wechselwirkungen · Simulect
Simulect 10 mg powder and solvent for solution for injection or infusion Simulect 10 mg powder for solution for injection or infusion · Abschnitt 4.5 · PDF-Seite 15
In the original phase III studies during the first 3 months post-transplantation, 14% of patients in the
basiliximab group and 27% of patients in the placebo group had an acute rejection episode treated with
antibody therapy (OKT 3 or antithymocyte globulin/antilymphocyte globulin [ATG/ALG]), with no
increase in adverse events or infections in the basiliximab group as compared to placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): placebo (HOS-088378)
Version 2025-12-19T11:51:00Z · SHA-256 733fba3a740348b21107babe9d9387936dfd68357cde53822fb186eb4a9d7e0d · Passage 944dd2ff5cb6a830b9a351682081aaa20bd0abcdc7c9ef7c7642176f7d4be91a · Zeichen 1050–1441 im Abschnitt
Wechselwirkungen · Simulect
Simulect 10 mg powder and solvent for solution for injection or infusion Simulect 10 mg powder for solution for injection or infusion · Abschnitt 4.5 · PDF-Seite 15
Three clinical trials have investigated basiliximab use in combination with a triple therapy regimen
which included either azathioprine or mycophenolate mofetil. The total body clearance of basiliximab
was reduced by an average 22% when azathioprine was added to a regimen consisting of ciclosporin
for microemulsion and corticosteroids. The total body clearance of basiliximab was reduced by an
average 51% when mycophenolate mofetil was added to a regimen consisting of ciclosporin for
microemulsion and corticosteroids. The use of basiliximab in a triple therapy regimen including
azathioprine or mycophenolate mofetil did not increase adverse events or infections in the basiliximab
group as compared to placebo (see section 4.8).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-12-19T11:51:00Z · SHA-256 733fba3a740348b21107babe9d9387936dfd68357cde53822fb186eb4a9d7e0d · Passage d9ac0d08b763395ed52ccfd6a3db09312ae59258cd52ba42239ca8173921e687 · Zeichen 1443–2177 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.